IL6 and breast cancer: The objective of the “JAKEE” Trial (NCT01594216) is to determine whether addition of ruxolitinib to exemestane is safe and could restore ET-sensitivity in women with ER+ BC who had relapsed or progressed after NSAI therapy, and to determine if biomarkers reflecting enhanced IL-6 signaling in the tumor microenvironment, such as increased serum inflammatory markers, increased estradiol levels and/or germline polymorphisms in host IL-6 promoter could identify participants more likely to respond to the combination.